3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
2
Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Stomach Neoplasms
1
Sarcoma
1
Penile Neoplasms
1
PD-L1 Positive Mutation Tumor
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
Hemangiosarcoma
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Epirubicin
3
Gemcitabine
2
tislelizumab
1
lornoxicam
1
catumaxomab
1
avelumab
1
apatorsen
1
VB4-845
1
Ty21a typhoid vaccine
1
Therapeutics
1
Radiotherapy
1
Postoperative Period
1
Ofloxacin
1
Multiparametric Magnetic Resonance Imaging
1
Mitomycin
1
Docetaxel
1
Cystoscopy
1
BCG Vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Non-Muscle Invasive Bladder Neoplasms
×
avelumab
×
Clear all
NCT03950362
2019-05-16
PREVERT
Institut Paoli-Calmettes
Phase 2
Unknown
67 enrolled